Ares Genetics, a division of molecular diagnostics company Curetis, has commenced the development of a new diagnostic test to detect microbial infections and predict responses to antimicrobial therapies.
The new ARESupa Universal Pathogenome Assay will leverage Curetis’ ARES Technology Platform and genetic antimicrobial resistance database, called ARESdb, for interpreting results.
The ARES Technology Platform is based on next-generation sequencing (NGS), while ARESdb is an artificial intelligence (AI) powered genetic pathogen reference database.
The ARESupa diagnostic test will be designed to detect nearly all types of pathogens in a variety of samples. The test is also expected to be able to use a single laboratory workflow to predict response to different antimicrobial drugs.
It will be initially offered as a laboratory test, with plans to obtain regulatory approvals for use as an in-vitro diagnostic (IVD) and subsequent commercialisation.
Currently, Ares Genetics is building a research and development (R&D) and diagnostic service lab at the Vienna BioCenter Campus in Vienna, Austria.
The facility will focus on supporting the in-house development and initial launch of the new diagnostic test as a laboratory-developed product in Europe.
Ares Genetics is also considering certain fast-track options to roll out the laboratory-developed version of ARESupa in the US. This launch will carried out only after completing development of first-generation of the test.
Ares Genetics managing director Achim Plum said: “With ARESupa, we intend to take molecular testing for microbial infections to the next level, leveraging the anticipated adoption of NGS technology in clinical diagnostics.”
Ares Genetics and Curetis have entered into an agreement with China-based firm MGI to create an integrated and fully automated platform for analysing different types of human samples for microbial infections using NGS.
Also, the company is in talks with other NGS technology providers to leverage their solutions for deploying ARESupa.